The new approach would reduce the time and cost of bringing new treatments to patients. Under the draft guidance, drugs tested prior to surgical removal of tumors in certain types of high-risk patients with localized, early-stage disease would have an accelerated approval, according to the release.
The proposal is based on the I-SPY 2 TRIAL, a Phase II breast cancer trial under the Biomarkers Consortium, a partnership led by FNIH.
The FDA is accepting public comment on the new recommendations through July.
More Articles on the FDA:
House Approves FDA Funding Bill to Reduce Drug Shortages
Federal Agencies Issue Recommendation to Prevent Needlestick Injuries
Teleflex Receives FDA Clearance for Epidural Catheter
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
